公开(公告)号：US20240043527A1

公开(公告)日：2024-02-08

申请号：US17915567

申请日：2021-03-29

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Claudia Lindemann ,  Jan Diekmann ,  Kerstin Brettschneider ,  Hayat Bähr-Mahmud ,  Ursula Ellinghaus ,  Leyla Fischer ,  Christiane Stadler ,  Özlem Türeci

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K2317/522 ,  C07K2317/14

Abstract: The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).

公开(公告)号：US20240158501A1

公开(公告)日：2024-05-16

申请号：US18468103

申请日：2023-09-15

Applicant: BioNTech SE ,  Astellas Pharma Inc.

Inventor： Ugur Sahin ,  Christiane Stadler ,  Leyla Fischer ,  Arne Jendretzki ,  Özlem Türeci ,  Fabrice Le Gall ,  Maria Kreuzberg

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/86

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/28 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73

Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

公开(公告)号：US20230287088A1

公开(公告)日：2023-09-14

申请号：US18019787

申请日：2021-07-29

Applicant: BIONTECH SE

Inventor： Karsten Beckmann ,  Anna Carle ,  Sandra Prassl ,  Claudia Paulmann ,  Christiane Stadler ,  Georg Falck ,  Leyla Fischer ,  Alexander Muik ,  Ugur Sahin ,  Caroline Scharf

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/10 ,  A61P31/14 ,  C07K2317/31 ,  C07K2317/92

Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.